Bruce Steel, MBA, CFA

Bruce is the President, co-founder, and Chief Business Officer of Equillium as well as the founder and Managing Director of BioMed Ventures. He maintains extensive relationships with world-class institutional investors, entrepreneurs, and executives developed over eighteen years of investing and operating in the biotech sector. Bruce was co-founder and CEO of Rincon Pharmaceuticals from 2004 until its acquisition in 2008; previously he was Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. He also served as Vice President in the Venture division of Imperial Bank.

Bruce served as or is a Board Observer or Member at: Aegea, Amplyx, Anaptys, Auspex, Breathe, CardioFocus, Celula, Compass, Edge, Genalyte, Histogenics, Laguna, NanoString, NeuroVia, OptiScan, Pathwork, Promedior, Receptos, Suneva, Tracon, and Zosano. Bruce received his Bachelor of Arts degree from Dartmouth College and Masters of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.